Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial
BMC Palliative Care · 2024
DOI: 10.1186/s12904-024-01554-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BMC Palliative Care, 2024. Verfasst von Rongbo Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Fentanyl, Analgesics, Opioid, Breakthrough Pain, Cancer Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Breakthrough cancer pain (BTcP) has a negative impact on patients' quality of life, general activities, and is related to worse clinical outcomes. Fentanyl inhalant is a hand-held combination drug-device delivery system providing rapid, multi-dose (25μg/dose) administration of fentanyl via inhalation of a thermally generated aerosol. This multicenter, randomized, placebo-controlled, multiple-crossover, double-blind study evaluated the efficacy, safety, and tolerability of fentanyl inhalant in treating BTcP in opioid-tolerant patients. METHODS: The trial was conducted in opioid-tolerant cancer patients with 1 ~ 4 BTcP outbursts per day. Each patient was treated and observed for 6 episodes of BTcP (4 with fentanyl inhalant, 2 with placebo). During each episode of targeted BTcP, patients were allowed up to six inhalations, with an interval of at least 4 min between doses. Primary outcome was the time-weighted sum of PID (pain intensity difference) scores at 30 min (SPID30). RESULTS: A total of 335 BTcP episodes in 59 patients were treated. The mean SPID30 was -97.4 ± 48.43 for fentanyl inhalant-treated episodes, and -64.6 ± 40.25 for placebo-treated episodes (p < 0.001). Significant differences in PID for episodes treated with fentanyl inhalant versus placebo was seen as early as 4 min and maintained for up to 60 min. The percentage of episodes reported PI (pain intensity) scores ≤ 3, a ≥ 33% or ≥ 50% reduction in PI scores at 30 min, PR30 (pain relief scores at 30 min) and SPID60 favored fentanyl inhalant over placebo. Only 4.4% of BTcP episodes required rescue medication in fentanyl inhalant group. Most AEs were of mild or moderate severity and typical of opioid drugs. CONCLUSION: Treatment with fentanyl inhalant was shown to be a promising therapeutic option for BTcP, with significant pain relief starting very soon after dosing. Confirmation of effectiveness requires a larger phase III trial. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05531422 registered on 6 September 2022 after major amendment, NCT04713189 registered on 14 January 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.
- First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
- Department of Thoracic Oncology, Suining Central Hospital, Suining, Sichuan, China.
- Department of Oncology, First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China.
- Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
- Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Zitieren
APA
Lin, R., Song, B., Li, N., Rong, B., Bai, J., Liu, Y., Wang, W., Liu, A., Luo, S., Liu, B., Cheng, P., Wu, Y., Li, Y., Yu, X., Liu, X., Dai, X., Li, X., Liu, D., Wang, J., & Huang, Y. (2024). Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. BMC Palliative Care. https://doi.org/10.1186/s12904-024-01554-9
Vancouver
Lin R, Song B, Li N, Rong B, Bai J, Liu Y, et al. Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. BMC Palliative Care. 2024. doi:10.1186/s12904-024-01554-9
BibTeX
@article{Lin2024,
author = {Lin, Rongbo and Song, Binbin and Li, Na and Rong, Biaoxue and Bai, Jinghui and Liu, Yong and Wang, Wei and Liu, Anwen and Luo, Suxia and Liu, Bo and Cheng, Peng and Wu, Yani and Li, Yujie and Yu, Xiaohui and Liu, Xueying and Dai, Xiangrong and Li, Xiaoyi and Liu, Dongying and Wang, Jian and Huang, Yan},
title = {Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial},
journal = {BMC Palliative Care},
year = {2024},
doi = {10.1186/s12904-024-01554-9}
}
EUVIMED